FDA granted accelerated approval to retifanlimab-dlwr for Merkel cell carcinoma in 2023
The agency cleared Incyte's Zynyz for adults with metastatic or recurrent locally advanced Merkel cell carcinoma.
On March 22, 2023, the Food and Drug Administration granted accelerated approval to retifanlimab-dlwr (Zynyz, Incyte Corporation) for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).1
The approval record, posted on the FDA's website, does not provide additional detail beyond the drug's name, manufacturer, approval date, and the specific indication.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.